---
title: "China Resources Pharmaceutical Subsidiary Tasly Posts Higher Profit on Lower Revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302866530.md"
description: "China Resources Pharmaceutical Group reported that its subsidiary, Tasly Pharmaceutical, posted higher net profit of roughly RMB 1.09 billion but lower revenue of about RMB 6.07 billion for the first nine months of 2026. The group holds a 28% stake in Tasly via China Resources Sanjiu. While Tasly's solid equity and reduced liabilities support the group's market footprint, the announcement cautioned that figures are unaudited and subject to adjustments."
datetime: "2026-10-23T10:40:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302866530.md)
  - [en](https://longbridge.com/en/news/302866530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302866530.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical Subsidiary Tasly Posts Higher Profit on Lower Revenue

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).

China Resources Pharmaceutical Group Ltd., a leading Hong Kong-incorporated healthcare group, consolidates Tasly Pharmaceutical Group Co., Ltd. as a subsidiary via a 28% stake held through China Resources Sanjiu. Tasly, listed in Shanghai, enhances the Group’s footprint in China’s pharmaceutical market through its portfolio of medicinal products and related healthcare offerings.

Tasly Pharmaceutical reported unaudited revenue of about RMB 6.07 billion and net profit of roughly RMB 1.09 billion for the nine months ended 30 September 2026, showing slightly lower sales but higher earnings year-on-year. The announcement highlights a decline in cash and cash equivalents alongside solid equity and reduced liabilities, while stressing that these figures cover Tasly alone, are subject to audit adjustments, and should be used cautiously by shareholders and potential investors when assessing China Resources Pharmaceutical’s overall performance.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Ltd. is a major Chinese healthcare conglomerate with operations spanning pharmaceuticals and medical products. Through its non-wholly-owned subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., it holds about 28% of Tasly Pharmaceutical Group Co., Ltd., which is treated as a subsidiary and contributes to the Group’s broader presence in the domestic pharmaceutical market.

Tasly Pharmaceutical, listed on the Shanghai Stock Exchange, operates in the pharmaceutical industry in the People’s Republic of China. It focuses on the development, manufacturing and sale of medicinal products, and its financial performance forms an important part of China Resources Pharmaceutical’s consolidated results and overall industry positioning.

**Average Trading Volume:** 8,017,719

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$29.25B

For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [600535.CN](https://longbridge.com/en/quote/600535.CN.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion](https://longbridge.com/en/news/303715107.md)
- [China Resources Pharma Subsidiary Starts Pre-Bidding for Potential Share Issuance](https://longbridge.com/en/news/302114112.md)
- [Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources Pharmaceutical](https://longbridge.com/en/news/292626345.md)
- [China Resources Pharmaceutical Completes RMB 800 Million Medium-Term Note Issuance](https://longbridge.com/en/news/302856714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**